08 Jul 2021

Small Cap Feast: 09/07/21

Diaceutics Plc (DXRX:LON), 122 | Mpac Group PLC (MPAC:LON), 375 | Polar Capital Holdings Plc (POLR:LON), 402 | RWS Holdings plc (RWS:LON), 82.6 | Surface Transforms PLC (SCE:LON), 0.6 | Deltex Medical Group plc (DTXMF:OTC), 0

- Hybridan Research Team
- 2 pages

Joiners: LungLife (LLAI.L), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence (AI), has joined AIM. The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve upon existing computer software to identify informative cells from blood, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications ....

Sign up to access

Get access to our full offering from over 30 providers

Get access to our full offering from over 30 providers

Small Cap Feast: 09/07/21

Diaceutics Plc (DXRX:LON), 122 | Mpac Group PLC (MPAC:LON), 375 | Polar Capital Holdings Plc (POLR:LON), 402 | RWS Holdings plc (RWS:LON), 82.6 | Surface Transforms PLC (SCE:LON), 0.6 | Deltex Medical Group plc (DTXMF:OTC), 0

Published: 08 Jul 2021
Author: Hybridan Research Team
Pages: 2

Joiners: LungLife (LLAI.L), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence (AI), has joined AIM. The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve upon existing computer software to identify informative cells from blood, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications ....

Top